Horizon Therapeutics Ireland DAC - Methods for Treatment of Thyroid Eye Disease (EP4021500A1)
Summary
EPO published patent application EP4021500A1 filed by Horizon Therapeutics Ireland DAC covering methods for treating thyroid eye disease. The application names Jeffrey Sherman as inventor and includes IPC classifications spanning immunology (A61K 39/395), monoclonal antibodies (C07K 16/28), and ophthalmic therapeutics (A61P 27/02).
What changed
EPO published patent application EP4021500A1 for methods of treating thyroid eye disease, with designated states covering all major European markets including DE, FR, GB, IT, ES, and NL. The application includes multiple pharmaceutical composition classifications and ophthalmic therapeutic designations.\n\nPharmaceutical companies developing thyroid eye disease treatments should review this patent for potential blocking positions and assess freedom-to-operate before advancing related therapeutic programs. Investors tracking Horizon Therapeutics' intellectual property portfolio should note the scope of claims across European jurisdictions.
What to do next
- Monitor EPO register for patent prosecution updates
- Assess freedom-to-operate for thyroid eye disease therapeutics
- Evaluate patent portfolio implications for competing treatments
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
Publication EP4021500A1 Kind: A1 Apr 01, 2026
Applicants
Horizon Therapeutics Ireland DAC
Inventors
SHERMAN, Jeffrey
IPC Classifications
A61K 39/395 20060101AFI20230802BHEP A61K 31/277 20060101ALI20230802BHEP A61K 31/365 20060101ALI20230802BHEP A61K 31/4545 20060101ALI20230802BHEP A61K 31/506 20060101ALI20230802BHEP A61K 31/5377 20060101ALI20230802BHEP A61K 39/00 20060101ALI20230802BHEP A61P 27/02 20060101ALI20230802BHEP C07K 16/28 20060101ALI20230802BHEP A61K 31/4985 20060101ALI20230802BHEP A61K 31/517 20060101ALI20230802BHEP A61K 31/519 20060101ALI20230802BHEP A61K 31/53 20060101ALI20230802BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.